Search

Avanafil

[L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113] … Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction.

Fructose

Guanoxan

Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

Edaravone

[L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in … [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.

Grazoprevir

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy … in combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593].

Glyceryl monostearate

It is commonly used as an emulsifier in foods.

Bunamiodyl

Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

Dantron

Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

Oxeladin

Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

Human papillomavirus type 16 L1 capsid protein antigen

It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.